Clinical Trial Update: Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial updates on switching from efavirenz to dolutegravir in HIV patients with central nervous system toxicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Sustiva (efavirenz)
• Tivicay (dolutegravir)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 4 | Status: UNKNOWN